BEAM•benzinga•
Leerink Partners Upgrades Beam Therapeutics to Outperform, Raises Price Target to $39
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 6, 2024 by benzinga